Galapagos NV
GLPG
$29.45
Share price
1.31%
Change (1 day)
-23.94%
Change (1 year)
Categories
Galapagos NV (GLPG) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : $1.93 B
According to Galapagos NV's latest financial reports the company's total liabilities are $1.93 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Galapagos NV - Total liabilities on balance sheet (from 2008 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $2.36 B | -18.1% |
| 2021-12-31 | $2.88 B | -22.96% |
| 2020-12-31 | $3.74 B | 4.79% |
| 2019-12-31 | $3.57 B | 1288.09% |
| 2018-12-31 | $0.25 B | -21.75% |
| 2017-12-31 | $0.32 B | -3.65% |
| 2016-12-31 | $0.34 B | 303.22% |
| 2015-12-31 | $84.75 M | 8.33% |
| 2014-12-31 | $78.24 M | -52.88% |
| 2013-12-31 | $0.16 B | 7.4% |
| 2012-12-31 | $0.15 B | 179.52% |
| 2011-12-31 | $55.31 M | -8.51% |
| 2010-12-31 | $60.45 M | 21.15% |
| 2009-12-31 | $49.9 M | 3.47% |
| 2008-12-31 | $48.23 M | -34.06% |
| 2007-12-31 | $73.14 M | -4.76% |
| 2006-12-31 | $76.8 M | 218.19% |
| 2005-12-31 | $24.13 M | 239.2% |
| 2004-12-31 | $7.11 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $98.78 B | 5,009.87% | 🇺🇸 USA |
 Abbott Laboratories ABT | $34.38 B | 1,678.76% | 🇺🇸 USA |
 AbbVie ABBV | $124.31 B | 6,330.48% | 🇺🇸 USA |
 Sanofi SNY | $57.61 B | 2,880.19% | 🇫🇷 France |
 Merck MRK | $69.04 B | 3,471.28% | 🇺🇸 USA |
 AstraZeneca AZN | $61.95 B | 3,104.69% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $58.82 B | 2,942.90% | 🇬🇧 UK |
 Fortress Biotech
FBIO | $0.16 B | -91.53% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.35 B | 1,728.73% | 🇮🇱 Israel |